BioCryst Pharmaceuticals, Inc. (BCRX)
Automate Your Wheel Strategy on BCRX
With Tiblio's Option Bot, you can configure your own wheel strategy including BCRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BCRX
- Rev/Share 2.6649
- Book/Share -2.0152
- PB -3.4835
- Debt/Equity -1.7527
- CurrentRatio 2.2492
- ROIC 0.188
- MktCap 1473641419.0
- FreeCF/Share 0.0753
- PFCF 93.4992
- PE -41.1247
- Debt/Assets 1.6162
- DivYield 0
- ROE 0.0786
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BCRX | Evercore ISI | Outperform | In-line | -- | $8 | Oct. 1, 2025 |
| Initiation | BCRX | Cantor Fitzgerald | -- | Overweight | -- | $20 | April 29, 2025 |
| Initiation | BCRX | Wedbush | -- | Outperform | -- | $15 | Feb. 25, 2025 |
News
Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
After losing some value lately, a hammer chart pattern has been formed for BioCryst (BCRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Read More
Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 84.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive
BioCryst Pharmaceuticals stock rose 9% since September, driven by strong Orladeyo sales and raised revenue guidance for 2025 to $535-$550 million. Orladeyo's convenience over injectable therapies is solidifying its market presence, with pediatric expansion and exclusivity until 2035 boosting growth prospects. Potential competition from Pharvaris' deucrictibant, but Orladeyo's market entrenchment and differentiation mitigate immediate threats.
Read More
BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
—ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)—
Read More
BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Additional real-world studies with ORLADEYO show statistically significant HAE attack rate reductions experienced by patients with C1-INH deficiency and normal C1-INH levels and function –
Read More
BioCryst to Present at Upcoming Investor Conferences
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
Read More
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Negative
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
BioCryst Launches ORLADEYO® (berotralstat) in Portugal
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Infarmed in Portugal has recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Portugal will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks.
Read More
BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025.
Read More
About BioCryst Pharmaceuticals, Inc. (BCRX)
- IPO Date 1994-03-04
- Website https://www.biocryst.com
- Industry Biotechnology
- CEO Jon P. Stonehouse
- Employees 580